Clinical Trial Update: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

View source ↗

Summary

A study evaluating locoregional therapy combined with Bevacizumab and a PD-1/PD-L1 inhibitor in advanced hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1/PD-L1 inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody | Status: RECRUITING